Giant Virus Has CRISPR-like Immune Defense

The genome of a mimivirus strain resistant to a virophage has repeated phage sequences alongside nuclease- and helicase-coding sections.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKMEDIA, PLOS BIOL, 7:e1000092, 2009A giant virus known as mimivirus possesses an immune program similar to CRISPR, a defense system evolved by bacteria and archaea and now adapted by scientists for genome editing, researchers reported in Nature this week (February 29). Like CRISPR, the viral version (dubbed MIMIVIRE) includes a stretch of host genome containing repeated sequences matching a pathogen’s along with genes that can destroy the invader’s genome.

The precise method of immunity still has to be deciphered, Francisco Mójica, a microbiologist at the University of Alicante in Spain, told Nature News. “It will certainly be of great interest to identify the mechanism involved in MIMIVIRE immunity,” he said, adding that he suspects it works differently from CRISPR.

Didier Raoult, a microbiologist at Aix-Marseille University in France, and colleagues had previously discovered that a virophage, called Zamilon, could infect mimivirus—but only two lineages (B and C). A third lineage of mimivirus (A) was resistant to the virophage.

Supposing the resistance might have roots in a CRISPR-like mechanism, Raoult’s team sequenced genomes from the three giant-virus lineages, and found a 28-nucleotide stretch of DNA in lineage A identical to a sequence in Zamilon. Part ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies